Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.7281
Dollar change
+0.0281
Percentage change
4.01
%
Index- P/E- EPS (ttm)-0.90 Insider Own0.24% Shs Outstand85.32M Perf Week4.14%
Market Cap62.12M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float85.11M Perf Month-12.70%
Income-92.36M PEG- EPS next Q- Inst Own27.28% Short Float0.48% Perf Quarter-23.33%
Sales79.26M P/S0.78 EPS this Y- Inst Trans-1.94% Short Ratio5.78 Perf Half Y-21.02%
Book/sh1.15 P/B0.63 EPS next Y- ROA-49.26% Short Interest0.41M Perf Year-75.81%
Cash/sh1.02 P/C0.71 EPS next 5Y5.10% ROE-67.18% 52W Range0.57 - 3.25 Perf YTD-21.71%
Dividend Est.- P/FCF- EPS past 5Y-21.64% ROI-84.84% 52W High-77.60% Beta0.23
Dividend TTM- Quick Ratio3.09 Sales past 5Y30.10% Gross Margin67.62% 52W Low27.25% ATR (14)0.07
Dividend Ex-Date- Current Ratio3.36 EPS Y/Y TTM33.50% Oper. Margin-128.83% RSI (14)45.56 Volatility11.15% 10.22%
Employees1138 Debt/Eq0.02 Sales Y/Y TTM-9.16% Profit Margin-116.53% Recom1.00 Target Price7.29
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q26.15% Payout- Rel Volume0.20 Prev Close0.70
Sales Surprise- EPS Surprise- Sales Q/Q-16.19% EarningsMar 28 AMC Avg Volume70.98K Price0.73
SMA20-2.82% SMA50-10.82% SMA200-38.69% Trades Volume14,198 Change4.01%
Date Action Analyst Rating Change Price Target Change
Oct-15-21Resumed Cowen Outperform
Jul-07-20Initiated Cowen Outperform
Mar-28-24 10:52PM
05:16PM
Jan-04-24 01:03AM
Dec-19-23 09:35PM
Dec-01-23 08:39AM
02:21AM Loading…
02:21AM
Nov-30-23 01:25AM
Nov-22-23 02:04AM
Nov-20-23 08:55PM
Oct-30-23 03:20AM
Oct-15-23 07:18PM
Sep-07-23 10:43PM
Sep-01-23 08:46AM
Aug-31-23 09:03PM
01:30AM
03:27AM Loading…
Aug-04-23 03:27AM
Jun-28-23 04:05AM
Jun-09-23 01:47PM
Jun-08-23 12:20AM
May-31-23 12:53PM
04:36AM
May-30-23 09:40AM
12:53AM
May-24-23 08:42AM
Apr-27-23 01:01AM
Apr-20-23 10:43PM
Apr-17-23 09:59AM
Mar-30-23 08:28AM
Mar-28-23 02:08AM
Mar-19-23 08:47AM
09:44AM Loading…
Mar-14-23 09:44AM
Mar-07-23 03:38AM
Jan-17-23 08:37PM
Jan-16-23 08:36AM
Jan-03-23 09:25AM
Dec-27-22 09:10AM
Dec-15-22 06:52AM
Nov-21-22 12:00PM
Nov-15-22 09:20PM
Nov-10-22 05:15AM
Nov-01-22 06:10AM
Oct-27-22 07:50AM
Oct-25-22 12:46AM
Oct-21-22 01:01PM
Oct-10-22 06:25AM
Sep-08-22 04:56AM
Aug-31-22 04:30PM
01:24PM
07:05AM
05:29AM
Aug-09-22 07:46AM
Aug-04-22 09:10AM
Aug-03-22 02:12AM
Jul-14-22 09:50PM
Jul-08-22 06:49AM
Jun-30-22 10:57AM
Jun-24-22 03:26AM
Jun-21-22 02:03AM
01:59AM
Jun-15-22 08:01AM
Jun-01-22 07:49AM
May-31-22 01:30PM
02:32AM
May-16-22 04:00AM
May-05-22 06:45PM
May-02-22 11:43AM
Mar-31-22 05:46AM
Mar-22-22 04:30PM
Mar-21-22 08:30PM
Mar-16-22 06:54PM
Mar-15-22 09:38AM
07:29AM
Mar-02-22 10:29AM
Feb-21-22 11:30PM
Jan-17-22 03:38PM
02:38PM
Dec-28-21 08:05PM
Dec-27-21 10:00PM
Dec-10-21 06:38PM
Nov-17-21 08:15PM
11:30AM
03:56AM
Nov-15-21 10:21PM
08:30PM
Nov-04-21 03:06AM
Nov-03-21 12:00AM
Aug-31-21 12:00PM
12:30AM
Aug-03-21 03:00AM
Aug-02-21 04:00AM
Jul-26-21 02:15AM
Jun-11-21 06:49AM
May-26-21 04:00AM
May-25-21 06:15AM
12:19AM
May-19-21 05:06AM
May-12-21 04:00AM
Apr-29-21 07:30AM
Apr-28-21 10:00PM
Apr-20-21 07:21AM
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.